Female cancer prediction using cervical omics to individualise screening and prevention

Informations projet

FORECEE

N° de convention de subvention: 634570

DOI 10.3030/634570

Projet clôturé

Date de signature de la CE 27 Mars 2015

Date de début 1 Septembre 2015

Date de fin 29 Février 2020

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total € 7 994 746,25

Contribution de l’UE € 7 994 746,25

Coordonné par

UNIVERSITY COLLEGE LONDON
United Kingdom

Livrables

Documents, reports (6)

Recommendations for screening policy from legal/regulatory/ethical and women’s perspective
Review on decision-analytic cost-effectiveness

Review on decision-analytic cost-effectiveness studies in women’s cancers (based on current screening/prevention strategies) analysis publication available

Cost-effectiveness in women’s cancer (based on WID test projections) analysis publication available
Leaflet and results from survey and public workshop results
Screening/prevention recommendations based on the WID test available
Scientific publication on the optimal delivery of risk-stratified screening, including consensus guidelines on implementation plan

Websites, patent fillings, videos etc. (3)

Project website
Multimedia presentation available
Formal presentation to the ESGO patient advocacy group (ENGAGe)

Formal presentation to the ESGO patient advocacy group ENGAGe

Publications

Peer reviewed articles (7)

Epigenetic Discrimination: Emerging Applications of Epigenetics Pointing to the Limitations of Policies Against Genetic Discrimination

Auteurs: Charles Dupras, Lingqiao Song, Katie M. Saulnier, Yann Joly
Publié dans: Frontiers in Genetics, Numéro 9, 2018, ISSN 1664-8021
Éditeur: Frontiers Media
DOI: 10.3389/fgene.2018.00202

Prediction models for endometrial cancer for the general population or symptomatic women: A systematic review

Auteurs: Maaike Alblas, Kimberley B. Velt, Nora Pashayan, Martin Widschwendter, Ewout W. Steyerberg, Yvonne Vergouwe
Publié dans: Critical Reviews in Oncology/Hematology, Numéro 126, 2018, Page(s) 92-99, ISSN 1040-8428
Éditeur: Elsevier BV
DOI: 10.1016/j.critrevonc.2018.03.023

Ethical, Legal, and Regulatory Issues for the Implementation of Omics-Based Risk Prediction of Women’s Cancer: Points to Consider

Auteurs: Emmanuelle Lévesque, Emily Kirby, Ineke Bolt, Bartha Maria Knoppers, Inez de Beaufort, Nora Pashayan, Martin Widschwendter
Publié dans: Public Health Genomics, 2018, Page(s) 1-8, ISSN 1662-4246
Éditeur: S. Karger AG
DOI: 10.1159/000492663

Epigenome-based cancer risk prediction: rationale, opportunities and challenges

Auteurs: Martin Widschwendter, Allison Jones, Iona Evans, Daniel Reisel, Joakim Dillner, Karin Sundström, Ewout W. Steyerberg, Yvonne Vergouwe, Odette Wegwarth, Felix G. Rebitschek, Uwe Siebert, Gaby Sroczynski, Inez D. de Beaufort, Ineke Bolt, David Cibula, Michal Zikan, Line Bjørge, Nicoletta Colombo, Nadia Harbeck, Frank Dudbridge, Anne-Marie Tasse, Bartha M. Knoppers, Yann Joly, Andrew E. Teschendorf
Publié dans: Nature Reviews Clinical Oncology, Numéro 15/5, 2018, Page(s) 292-309, ISSN 1759-4774
Éditeur: Nature Publishing Group
DOI: 10.1038/nrclinonc.2018.30

What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries

Auteurs: Odette Wegwarth, Martin Widschwendter, David Cibula, Karin Sundström, Rosalba Portuesi, Ines Lein, Felix G Rebitschek
Publié dans: BMJ Open, Numéro 8/12, 2018, Page(s) e023789, ISSN 2044-6055
Éditeur: BMJ Publishing Group
DOI: 10.1136/bmjopen-2018-023789

Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges

Auteurs: Nora Pashayan, Daniel Reisel, Martin Widschwendter
Publié dans: Personalized Medicine, Numéro 13/2, 2016, Page(s) 93-95, ISSN 1741-0541
Éditeur: Future Medicine Ltd.
DOI: 10.2217/pme.15.53

Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management

Auteurs: Vit Weinberger, Marketa Bednarikova, David Cibula, Michal Zikan
Publié dans: Expert Review of Anticancer Therapy, Numéro 16/12, 2016, Page(s) 1311-1321, ISSN 1473-7140
Éditeur: Future Drugs Ltd.
DOI: 10.1080/14737140.2016.1247699

Non-peer reviewed articles (1)

Autonomy Challenges in Epigenetic Risk-Stratified Cancer Screening: How Can Patient Decision Aids Support Informed Consent?

Auteurs: Maaike Alblas, Maartje Schermer, Yvonne Vergouwe, Ineke Bolt
Publié dans: Journal of Personalized Medicine, Numéro 9/1, 2019, Page(s) 14, ISSN 2075-4426
Éditeur: Jourmal of Personalized Medicine
DOI: 10.3390/jpm9010014